JP2023546970A5 - - Google Patents
Info
- Publication number
- JP2023546970A5 JP2023546970A5 JP2023525457A JP2023525457A JP2023546970A5 JP 2023546970 A5 JP2023546970 A5 JP 2023546970A5 JP 2023525457 A JP2023525457 A JP 2023525457A JP 2023525457 A JP2023525457 A JP 2023525457A JP 2023546970 A5 JP2023546970 A5 JP 2023546970A5
- Authority
- JP
- Japan
- Prior art keywords
- subject
- cyp
- beta
- hydroxylase inhibitor
- plasma
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063105745P | 2020-10-26 | 2020-10-26 | |
| US63/105,745 | 2020-10-26 | ||
| US202163223719P | 2021-07-20 | 2021-07-20 | |
| US63/223,719 | 2021-07-20 | ||
| PCT/US2021/056499 WO2022093714A1 (en) | 2020-10-26 | 2021-10-25 | Cyp11b2 beta hydroxylase inhibitors for hypertension |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023546970A JP2023546970A (ja) | 2023-11-08 |
| JP2023546970A5 true JP2023546970A5 (cg-RX-API-DMAC7.html) | 2024-10-30 |
Family
ID=81384356
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023525457A Pending JP2023546970A (ja) | 2020-10-26 | 2021-10-25 | 高血圧のためのcyp11b2ベータヒドロキシラーゼ阻害剤 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20240009201A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4232011A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2023546970A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022093714A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20230069126A (ko) * | 2020-09-15 | 2023-05-18 | 미쓰비시 타나베 파마 코퍼레이션 | 트리아진 화합물의 염, 그 결정형 및 제조 방법 |
| KR20240052937A (ko) * | 2021-07-20 | 2024-04-23 | 미네랄리스 테라퓨틱스, 아이엔씨. | 이치환된 1, 2, 4-트리아진 화합물의 염을 포함하는 가용성 약제학적 조성물 |
| EP4466021A4 (en) * | 2022-01-19 | 2026-01-14 | Mineralys Therapeutics Inc | METHODS OF TREATING HYPERTENSION BY PERIODIC SUPPRESSION OF ALDOSTERONE SYNTHASE |
| EP4577217A4 (en) * | 2022-08-23 | 2026-08-12 | Mineralys Therapeutics Inc | METHODS OF TREATING HYPERTENSION WITH A COMBINATION OF AN ALDOSTERONE SYNTHASE INHIBITOR AND A DIURETIC |
| KR20250053914A (ko) * | 2022-08-23 | 2025-04-22 | 미네랄리스 테라퓨틱스, 아이엔씨. | 비만 대상체에서 고혈압을 치료하는 방법 |
| CN119789855A (zh) | 2022-09-02 | 2025-04-08 | 爱普宁公司(特拉华) | 治疗睡眠呼吸暂停的方法和组合物 |
| IL327143A (en) * | 2023-09-15 | 2026-05-01 | Mineralys Therapeutics Inc | Process for producing triazine compounds |
| CN120904169B (zh) * | 2024-05-30 | 2026-06-19 | 浙江扬厉医药技术有限公司 | 一种n-烷氧基乙酰胺类化合物、其药物组合物及其应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2459468T3 (es) * | 2009-05-15 | 2014-05-09 | Novartis Ag | Arilpiridinas como inhibidores de aldosterona sintasa |
| DE102012200360A1 (de) * | 2012-01-11 | 2013-07-11 | Bayer Intellectual Property Gmbh | Substituierte Triazine und ihre Verwendung |
| WO2014179186A1 (en) * | 2013-04-30 | 2014-11-06 | Boehringer Ingelheim International Gmbh | Aldosterone synthase inhibitors |
| MY176401A (en) * | 2014-04-24 | 2020-08-05 | Mitsubishi Tanabe Pharma Corp | Novel disubstituted 1,2,4-triazine compound |
| JP6314196B2 (ja) * | 2015-10-22 | 2018-04-18 | 田辺三菱製薬株式会社 | 医薬組成物 |
-
2021
- 2021-10-25 US US18/250,402 patent/US20240009201A1/en active Pending
- 2021-10-25 WO PCT/US2021/056499 patent/WO2022093714A1/en not_active Ceased
- 2021-10-25 JP JP2023525457A patent/JP2023546970A/ja active Pending
- 2021-10-25 EP EP21887273.7A patent/EP4232011A4/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Moreau et al. | Increasing daily walking lowers blood pressure in postmenopausal women | |
| Sullivan et al. | Hemodynamic and antihypertensive effects of captopril, an orally active angiotensin converting enzyme inhibitor. | |
| WO2007098390A2 (en) | Method for treating resistant hypertension | |
| VAUGHAN jR et al. | Hemodialysis-resistant hypertension: control with an orally active inhibitor of angiotensin-converting enzyme | |
| WO2007098387A2 (en) | Antihypertensive therapy | |
| JP2011190199A (ja) | 関節リウマチ薬 | |
| CN110545819A (zh) | 用于治疗高血压的组合物 | |
| FROLICH et al. | Reduction of plasma renin activity by inhibition of the fatty acid cyclooxygenase in human subjects: independence of sodium retention | |
| JP2025503015A5 (cg-RX-API-DMAC7.html) | ||
| Oparil et al. | Effects of candesartan cilexetil in patients with severe systemic hypertension | |
| Staessen et al. | Double-blind comparison between propranolol and bendroflumethiazide in captopril-treated resistant hypertensive patients | |
| EP2446885B1 (en) | Therapeutic agent for hypertension or normal high blood pressure | |
| KR20250084121A (ko) | 매일 1회 복용 알도스테론 합성효소 저해제 (R)-(+)-5-(p-시아노페닐)-5,6,7,8-테트라하드로이미다조[1,5-a]피리딘 | |
| Bălan et al. | Comparing different treatment schedules of Zomen (zofenopril) | |
| EP2586442A1 (en) | Sustained-release therapeutic agent for hypertension and renal dysfunction | |
| US20250302802A1 (en) | Methods and compositions | |
| Fuenfstueck et al. | Efficacy and safety of combination therapy using high-or low-dose hydrochlorothiazide with valsartan or other angiotensin-receptor blockers | |
| ES2332884T3 (es) | Tratamiento de la lipodistrofia con inhibidores del sistema renina angiotensina. | |
| TW202416996A (zh) | 治療肥胖個體之高血壓的方法 | |
| TW202416985A (zh) | 醛固酮合酶抑制劑與利尿劑組合治療高血壓之方法 | |
| RU2515482C1 (ru) | Способ профилактики развития мозговых нарушений и осложнений сердечно-сосудистых заболеваний в предгипертоническом состоянии | |
| TW201330848A (zh) | 治療黑種病人高血壓之方法 | |
| JP2012254975A (ja) | Ace阻害剤とl−アルギニンを含有する医薬組成物 | |
| WO2025202421A1 (en) | Methods and compositions | |
| JP2009256209A (ja) | 降圧療法 |